158 results about "Chemotherapy effects" patented technology

The invention discloses a cancer chemosensitivity prediction technique based on a molecular subnet and a random forest classifier. The method is characterized by comprising the steps of fusing data of oncogene expression profile, information of tumor mutation genome information and information of protein-protein interaction group, and excavating carcinogenic and cancer suppressor gene molecular subnets to realize feature extraction; taking the feature extraction as an input feature, designing a training model based on a random forest algorithm, and using the training model to be used for the testing of an independent test set, so as to obtain a chemosensitivity assessment of a patient. If the method provided by the invention is used for screening patients with effective chemotherapy effects before chemotherapy, the method has a significant meaning on cancer therapy.

The invention discloses an exosome-nucleic acid aptamer liposome composite drug carrier system which comprises an anti-tumor medicine, wherein the surface of the anti-tumor medicine is wrapped by nano-liposomes, a nucleic acid aptamer is connected with the surfaces of the nano-liposomes through chemical bonds to form a nucleic acid aptamer liposome on which the anti-tumor medicine is carried; thenucleic acid aptamer liposome on which the anti-tumor medicine is carried is compounded with exosome. The invention further discloses a preparation method and an application of the composite drug carrier system. The composite drug carrier system is good in targeting property, good in immune evasion property, free of cytotoxicity and not liable to be degraded by macrophage, can be applied to anti-tumor medicine chemotherapy of cancer patients, is capable of greatly improving the treatment effect of anti-tumor medicines, reducing the situations of chemotherapy effect degradation and disease reoccurrence caused by drug resistance, and alleviating the bottle neck problems of conventional chemotherapy of cancer patients, and has great application values and application prospects in intensifyingcancer treatment effects.

The invention discloses a mercapto-containing chitosan derivative, a compound nano particle and a preparation method. The preparation method of the mercapto-containing chitosan derivative includes steps of: (1) preparing a polyethylene glycol-based chitosan; (2) adding a partially-sulfhydrylated polyethylene imine to the polyethylene glycol-based chitosan to mix, adding a catalyst, carrying out a reaction, filtering the mixture, dialyzing with pure water, freeze drying to obtain the mercapto-containing chitosan derivative. The mercapto-containing chitosan derivative contains abundant active groups and can be widely used in the biomedical technical fields of medicament carriers, gene carriers, hybrid materials, etc. A mercapto-containing antineoplastic pro-drug is combined with gold nanorods by Au-S bonds to obtain to obtain a compound nano particle of the mercapto-containing chitosan derivative, wherein the nano particle has dual functions of photothermal therapy and chemotherapy]. The nano particle, with good stability under a high temperature condition or a laser-irradiation condition due to a strong chemical bonding effect, has not only a chemotherapy effect as an antineoplastic drug but also an photothermal-ablation effect on tumours.

Systems and methods stimulate circulatory activity in a targeted body region of an individual by applying ultrasound energy. Before, during or after the application of ultrasound energy, the systems and methods administer an agent to individual that results, e.g., in an angiogenic effect, or in a reduction of blood perfusion, or a chemotherapy effect. The application of ultrasound energy selectively increases blood perfusion or uptake of the agent in the targeted body region.

The invention relates to novel chloroethyl nitrosourea with anticancer activity and a synthesizing method thereof. The chloroethyl nitrosourea is a compound with a structure of the general formula (I), wherein n is an integer of 2 to 6. The chloroethyl nitrosourea can be used for treating gliomatosis cerebri, colon cancer and leukemia; compared with the existing nitrosourea-type anticancer medicine, the drug resistance is lower, the chemical therapy effect is better, the preparation method is simple in operation, the reaction yield is high, the toxicity is small, the cost is low, the method is suitable for the industrialized production, the development prospect is wide, and the application value is good.

The invention relates to a rectal cancer preoperative concurrent neoadjuvant radiotherapy and chemotherapy effect evaluation system and method. The evaluation system comprises: an image acquisition unit for acquiring MRI images before neoadjuvant radiotherapy and chemotherapy for patients with the locally advanced rectal cancer, and dividing the rectal cancer patients into a training set, a checkset and a test sets as input image data; an image annotation unit for performing data annotation on MRI images of the training set, the check set and the test set; a convolutional neural network construction unit for constructing a first convolutional neural network model; and a convolutional neural network model training unit for acquiring a second convolutional neural network model for evaluating the rectal cancer preoperative concurrent neoadjuvant radiotherapy and chemotherapy effect. The rectal cancer preoperative concurrent neoadjuvant radiotherapy and chemotherapy effect evaluation system has many advantages such as high accuracy, short time-consuming, long working duration, objective and three-dimensional result.

The invention discloses a method for preparing cisplatin polymer micelles and application of the cisplatin polymer micelles. The method comprises: grafting poly asparagus imide with amino polyethylene glycol monomethyl ether to obtain polyethylene glycol-g-poly asparagus imide; dissolving the polyethylene glycol-g-poly asparagus imide product into a mixed system of triethylamine and water, and opening loop by glutamic acid or aspartic acid, so as to obtain polyethylene glycol-g-poly(aspartic acid) amino acid derivatives; and dissolving the derivatives and cisplatin into an aqueous-phase system, and obtaining the cisplatin polymer micelles through complexation of carboxyl groups and metals. The cisplatin polymer micelles are applied to treatment of oophoroma, cervical cancer, testis cancer, breast cancer, esophagus cancer, non-small cell lung cancer and gastric cancer. The obtained cisplatin polymer micelles have the particle diameter which can be controlled to be between 80 and 200 nanometers, and have good passive targeting property. Compared with cisplatin micromolecular anticarcinogen, the cisplatin polymer micelles have better chemotherapy effect and low toxicity.

The invention discloses an application of SNHG5 (small nucleolar RNA host gene 5) in diagnosis, evaluation and efficacy prediction of breast cancer. It is found that lncRNA SNHG5 has significant low expression in breast cancer tissue and breast cancer cell lines, knockout of the lncRNA SNHG5 gene can enhance proliferation and migration of breast cancer cells and inhibit apoptosis, and thus, the expression level of long-chain non-coding RNA SNHG5 is closely related with diagnosis, transfer and relapse of tumor, patient prognosis and neoadjuvant chemotherapy effect are closely related, which indicates that the lncRNA SNHG5 gene can be used as a marker for diagnosis, prognosis evaluation or effect prediction. A breast cancer cell model which has low expression of SNHG5 and is established by transfecting breast cancer cell lines with small interference RNA can be used in a preparation method of a preparation for preventing relapse and transfer of breast cancer.

The invention discloses functional lipidosome for treating a brain tumor and a preparing method and application thereof. The target lipidosome is composed of lipidosome and 4-aminophenyl-alpha-D-pyran mannoside; 4-aminophenyl-alpha-D-pyran mannoside is connected to an amino group of the lipidosome, an amino groupd of the lipidosome is provided by distearoyl phosphatidyl ethanolamine-polyethylene glycol-amidogen. The surface of the lipidosome is modified by MAN, the capacity for striding blood brain barrier is enhanced, and the functional lipidosome has the function of targeting tumor cells; the antineoplastic drug ursolic acid and an iagent EGCG for inducing tumor cell apoptosis are encapsulated into the lipidosome to obtain multifunctional target brain tumor stem cell compound lipidosome so that a drug can reach the focus position after striding the BBB, the two drug materials are combined to kill tumor cells and induce tumor cell apoptosis, the chemotherapy effect is greatly improved, and the functional lipidosome is expected to effectively prevent tumor relapse. The functional lipidosome brings hope for thoroughly radical treatment the brain tumor and has important theoretical significance and clinical significance.

The invention provides a thermosensitive polymer-modified bivalent platinum nanocluster and a preparation method and application thereof. The bivalent platinum nanocluster has a core-shell structure,the inner core comprises zero-valent platinum with divalent platinum on the surface and the shell is a temperature-sensitive polymer. The preparation method utilizes a thermosensitive polymer ligand as a template to synthesize bivalent platinum nanoclusters with different relative contents of divalent platinum and zero-valent platinum. Through adjustment and control of the relative content of divalent platinum and zero-valent platinum, the relative interaction intensity of the photothermal effect and the chemotherapy effect is precisely adjusted and controlled so that photothermal chemotherapy-combined anti-tumor effects are optimized.

The invention relates to a cell membrane coated ultra-small ferroferric oxide nanocluster, and a preparation method and an application thereof. The method comprises the following steps: preparation ofultra-small ferroferric oxide nanoparticles, preparation of surface aminated ultra-small ferroferric oxide nanoparticles, preparation of ferroferric oxide nanoclusters, preparation of adriamycin-loaded ferroferric oxide nanoclusters, preparation of a cell suspension, and preparation of cell membrane coated ultra-small ferroferric oxide nanoclusters. After the nanocluster provided by the inventionis injected into a mouse body through a tail vein, T1 / T2 bimodal MR imaging conversion can be achieved; meanwhile, the anti-tumor effect can be exerted; the chemotherapy effect of the nanocluster canbe further enhanced through a UTMD auxiliary means; and the nanocluster has potential clinical application value.

The invention discloses microwave sensitization composite nano particles as well as a preparation method and application thereof. The microwave sensitization composite nano particles are hollow PLGA nano particles and wrap NaCL and adriamycin, mPEG-PLGA is dissolved in dichloromethane, a mixed aqueous solution dissolved with polyvinyl alcohol, NaCL and adriamycinis added for emulsification, the dichloromethane is removed in a magnetic stirring manner, and finally the solution is centrifuged, precipitated and cleaned for multiple times, thus obtaining the microwave sensitization composite nanoparticles. The microwave sensitization composite nano particles can be applied to the tumor ablation treatment process so as to improve the sensitivity of tumor cells to a microwave and chemotherapy effect, thereby realizing a synergistic effect of microwave ablation, non-thermal effect and chemotherapy on the tumor.

The invention discloses a compound used for manufacturing an auxiliary therapeutic agent for chemotherapy cancer patients; the compound mainly comprises fermentation soybean abstract, green tea abstract, spirulina, turmeric abstract, antrodia mycelium, and grape seed abstract; the compound can prevent colorectal polyps from canceration, and improves chemotherapy effect, prolongs cancer patient survival period, and reduces non-deteriorate survival period / and chemotherapy side effects; the compound also provides anti-inflammation activity, and effectively reduces generation of inflammation mediums like PGE2, NO, -alpha (TNF-alpha) and -6(IL-6).

The invention discloses a bionic nano-carrier and an application thereof in preparation of brain glioma treatment medicines, and belongs to the technical field of medicines. The bionic nano-carrier comprises a long-circulating liposome and a hybrid cell membrane; the long-circulating liposome serves as an inner core, the hybrid cell membrane serves as a shell, and the long-circulating liposome is coated with the hybrid cell membrane; and the hybrid cell membrane is formed by mixing an immune cell membrane and a tumor cell membrane. According to the nano-carrier disclosed by the invention, the long-circulating liposome is taken as a core, the core is coated with a hybrid cell membrane of immune cells and tumor cells, the nano-carrier moves and passes through a blood-brain barrier through the interaction of surface protein of the immune cells and receptors on brain endothelial cells, and meanwhile, the enhanced tumor targeting capability is realized through homologous targeting and homing effects, targeted treatment of brain glioma is achieved, and the chemotherapy effect is improved.

The invention discloses composition based on main components of Pu'er tea and the application thereof. The composition comprises tea brown pigment, tea polysaccharide, tea polyphenol, caffeine, gamma-aminobutyric acid and gallic acid. A wild type mouse embryo fibroblast is utilized to test the killing effect of DNA toxicity chemical substance to normal cells and the effect that the composition provided by the invention protects the normal cells from DNA damage and prevents apoptosis; the result shows that the composition provided by the invention can effectively prevent the normal cell death caused by DNA toxicity chemical substance; and further research shows that the composition provided by the invention does not protect tumor cell death caused by the DNA toxicity chemical compound, conversely, the composition provided by the invention can promote the killing effect of the DNA toxicity chemical compound to the tumor cells. Therefore, the composition can be used for protecting the normal cells during the chemotherapy of tumor patients and alleviating toxic side effects caused by tumor chemotherapy, and meanwhile sensibilizes chemotherapy drug, enhances chemotherapy effect, and improves survival quality of chemotherapy patients.

The invention discloses local chemotherapy equipment for tumors. The local chemotherapy equipment comprises a needle cylinder and a liquid medicine box, wherein a piston is slidably mounted in the needle cylinder; an injection port is formed in the front end of the needle cylinder; a liquid inlet is formed in one side of the front end of the needle cylinder; the top surface of the piston is fixedly connected with a push-pull rod; the top end of the push-pull rod extends to the outer side of the needle cylinder; the top of the liquid medicine box is provided with a liquid adding opening and a sealing cover installed on the liquid adding opening in a sealed mode; the bottom of the liquid medicine box is provided with a liquid outlet; an electric heating pipe is installed in the liquid medicine box; the liquid outlet is communicated with the liquid inlet through a liquid conveying catheter; the injection port is connected with an injection catheter; and the tail end of the injection catheter is connected with a puncture needle. According to the invention, chemotherapy is carried out on tumors through fixed-point puncture injection, so targeted local chemotherapy can be carried out onthe tumors, the side effects of tumor chemotherapy are reduced, and the comfort degree of a patient during chemotherapy is improved; and chemotherapy liquid medicine is stored and heated through the liquid medicine box, and chemotherapy effect is improved through the chemotherapy medicine with physical energy heating effect.

The invention belongs to the field of stem cells and biotechnology, and relates to a novel application of adipose-derived mesenchymal stem cells. Firstly, the invention provides a method for constructing adipose-derived mesenchymal stem cells carrying miR-122. In addition, the invention also discloses an application of the adipose-derived mesenchymal stem cells carrying miR-122 in the preparation of liver cancer chemosensitization preparations. The adipose-derived mesenchymal stem cells (AMSC) carrying miR-122 are used for preparing a chemosensitization agent and are combined with clinically conventional chemotherapeutic drugs so as to be applied to the chemotherapy of a liver cancer tumor-bearing mice model, so that the sensitivity of heterotopic or in-situ tumor tissues to the chemotherapeutic drugs can be obviously improved, the chemotherapy effect is enhanced, and the progress of the liver cancer is blocked. The dosage of the chemotherapeutic drugs can be reduced, and the chemotherapy side reaction is alleviated. The invention provides a technical support for preparing a novel liver cancer chemotherapy targeting sensitizer and a new method for the system chemotherapy of the liver cancer.

The invention discloses an application of vanillin in preparation of a nicotinamide-N-methyltransferase inhibitor. The inhibitor is prepared from traditional Chinese medicine monomer vanillin and pharmaceutically acceptable auxiliary materials. According to the invention, proliferation of various colorectal cancer cell strains is inhibited by inhibiting the expression of NNMT and enzyme activity in vitro and vivo, and an anti-tumor effect is achieved. Studies show that vanillin can weaken the drug resistance of colorectal cancer cell strains to 5-FU caused by high expression of NNMT in vitro,so that the chemotherapy sensitivity is enhanced; the apoptosis of the colorectal cancer cell strains with high expression of NNMT is increased by inducing ROS production and mitochondrial damage in cells; and the inhibitory effect of 5-fluorouracil on tumor proliferation and the apoptosis rate can be improved, so as to enhance the chemotherapy effect. The vanillin can be used as an NNMT inhibitorfor preparing anti-colorectal cancer drugs or adjuvant chemotherapy drugs, and has a good application prospect.

The invention relates to the biomedical professional field, in particular to an interferon-related kit for evaluating prognosis and predicting chemotherapy effect in gliomas. The present invention describes for the first time the state of interferon in gliomas, the first interferon-related model in glioma is established, The model is transformed into a kit to distinguish the status of interferon,to guide the diagnosis of glioma, to predict the poor prognosis and chemosensitivity, and to explain the instability of interferon therapy in glioma, and to provide constructive guidance strategy forfinding the best subset of patients suitable for interferon therapy.

An anticancer sustained-release gel injection sustained-release microspheres containing platinum-based compound, amphiphilic block copolymer, solvent and release regulator, the mixture of amphiphilic block copolymer and solvent has a temperature sensitive gelatinization characteristic, and can automatically become non-flowing degradable water insoluble gel, which can locally and slowly release drug at tumor foci for several weeks to several months, after injection into body. The adjuvant in the sustained-release microspheres is poly(lactic acid)-glycollic acid copolymer; and the amphiphilic block copolymer is PLGA-PEG-PLGA copolymer. The preparation can be injected into artery, inside a tumor or around a tumor with remarkably reduced systemic toxicity of drug, and can be used for solid tumors at different stages. The platinum-based compound is selected from nedaplatin, carboplatin, cisplatin, enloplatin, ormaplatin, sulfato-1,2-diaminocyclohezane-platinum (SHP), picoplatin, cyclopentylamine platium, zeniplatin, spiroplatin, lobaplatin, iproplatin, oxaliplatin, cycloplatin, and dexormaplatin. The preparation can be used with radioactive particles and can enhance chemotherapy effect.

The invention discloses a marker for predicting the chemotherapy effect of cervical squamous carcinoma and a screening method and application of the marker. The marker is at least one of SRSF7, SNRPB,SNRPA, SF3A2 and PQBP1 genes. The invention also discloses application of a reagent for detecting the marker for predicting the chemotherapy effect of cervical squamous carcinoma in preparation of aproduct for predicting the cisplatin-based combined radiotherapy and chemotherapy effect of cervical squamous carcinoma. The reagent is used for detecting the frequency or expression level of the SRSF7, SNRPB, SNRPA, SF3A2 or PQBP1 genes. The genes screened by the invention can accurately distinguish patients with radiotherapy and chemotherapy responses from patients without radiotherapy and chemotherapy responses, and the patients can be assisted to select different treatment modes by utilizing the genes.

The invention discloses a gene capable of determining the sensitivity of tumour cells to chemotherapy drugs, which is named TJP1 or ZO-1. The invention also discloses a method for predicting the chemotherapeutic effect on tumour by using the gene, and patients in which TJP1exrpression exists are sensitive to the chemotherapy drugs; and the patients suffering the loss of expression of TJP1 are endowed with tolerance to the chemotherapy drugs. The invention also discloses a method for improving the chemotherapeutic effect by improving or inducing TJP1 expression as well as the application of the gene to the prediction of chemotherapeutic effect on tumour, the increasing of tumour chemotherapy sensitivity and the preparation of oncotherapy drugs. The invention can be beneficial to the development of a TJP1 / ZO-1 expression related diagnostic reagent kit so as to predict the chemotherapeutic effect on patients, and also beneficial to the screening of anticarcinogen so as to find out chemical and biological molecules inducing the TJP1 / ZO-1 expression, thereby finally achieving the purposes of reducing the times of chemotherapy, increasing the recovery rate, alleviating the toxic side effects of the chemotherapy drugs, saving the hospitalization costs and generating outstanding economic and social benefits.

The invention relates to the technical field of medical instruments, and discloses an esophagus cancer local chemotherapy tube. The tube comprises an outer cannula, a plurality of through grooves, a plurality of spraying heads, a connecting tube, an inner cannula and a chemotherapy tube joint; the through grooves are circumferentially and symmetrically formed in the outer cannula uniformly in thelength direction of the outer cannula, the cross section of each through hole is two symmetrical structures in a shape like the Chinese character of 'ao', and the spraying heads are correspondingly arranged in the through holes and move up and down along the through grooves; spraying holes are formed in the spraying heads, the spraying heads are respectively connected to the outer end of the connecting tube, the inner end of the connecting tube is communicated with the lower end of the inner cannula through a first tube joint, and the upper end of the inner cannula penetrates out of the upperend of the outer cannula and is communicated with chemotherapy tube joint. The esophagus cancer local chemotherapy tube relieves the chemotherapy pain of patients and improves the chemotherapy effectof the esophagus cancer.

The invention relates to taxol-based small-molecule hydrogel and a preparation method thereof. The preparation method of the taxol-based small-molecule hydrogel comprises the following steps of: (1) dissolving taxol derivatives obtained by ester bond connection of taxol and hydrophilic compounds through hydroxyl groups into an aqueous medium, wherein the quality of the taxol derivatives dissolved in 1ml of aqueous medium is 5-200mg; and (2) hydrolyzing ester bonds for connecting the taxol and the hydrophilic compounds to obtain taxol, thereby forming the taxol-based small-molecule hydrogel. The degree of hydrolyzing can be defined according to specific conditions so long as the hydrogel can be formed. The invention has the following beneficial effects: the synthesis method is simple and only needs 1-2 reaction steps, and the normal saline or buffer solution of the taxol derivatives forms the small-molecule hydrogel capable of being injected through self-hydrolyzing of the ester bonds; and secondly, a slow-release system takes drug molecules as carriers, and the hydrogel can be locally injected to tumor parts, thereby improving the chemotherapy effect.

The present invention provides a dispersible tablet dosage form of doxifluridine, which is characterized by its speedy decentralization and dissolution when being in vitro. Through clinical applications, it is found that compared to common doxifluridine capsules, the clinical curative effect is considerably improved, at the same time the adverse reaction is remarkably reduced and unexpected effects are acquired. In accordance with the present invention, for extensive cancer patients executing chemotherapy by adopting doxifluridine, the pains of chemotherapy are considerably alleviated, the neoplastic chemotherapy effect is improved, and said medicine has prodigious clinical use values; 5-FU is a specific anti-metabolizing medicine during the S period, and the unexpected effects obtained in accordance with the present invention are of good enlightening significance for researching pharmacodynamics features and mechanism of action of doxifluridine. In addition, it is convenient for aged and children to take the medicine in accordance with the present invention, with stable formulation, fast absorption, high bioavailability and few adverse reaction, which can be used as medicine for treating breast carcinoma, cancer of stomach, carcinoma of colon, restocarcinoma, nasopharyngeal carcinoma and the like.

The invention discloses a PDZ protein molecule NHERF1 related to cisplatin resistance, and applications thereof, and belongs to the field of biological treatment of tumors. The invention further discloses a PDZ protein molecule NHERF1 related to cisplatin resistance, wherein the PDZ protein molecule NHERF1 is lowly expressed in cisplatin-resistant cervical cancer cell lines and is the new cisplatin-resistant cervical cancer marker, such that the new target is provided for the design of drugs resisting the cisplatin resistance of cervical cancers, and the new drug directly for the cisplatin resistance of cervical cancers can be designed and developed based on the new target; and the PDZ protein molecule NHERF1 has the biological function and mechanism of the promotion of the drug resistanceof cervical cancer cells so as to provide the effective approach for the effective reversing of the cisplatin resistance of cervical cancers and the improving of the clinical chemotherapy effects ofcervical cancers.

The invention discloses a microRNA (ribonucleic acid) molecule MiR-141 related to tamoxifen resistance and an application of the microRNA molecule MiR-141 and belongs to the field of tumor biotherapy. The nucleotide sequence of the microRNA molecule MiR-141 related to tamoxifen resistance is shown as SEQ ID. No.1. The MiR-141 has the characteristics of low expression in ER (estrogen receptor) positive breast cancer tamoxifen resistant cells and high expression in ER positive breast cancer tamoxifen sensitive cells, and is a novel breast cancer tamoxifen resistance marker. Therefore, a novel target is provided for design of a drug resisting breast cancer tamoxifen resistance, and on the basis, the target is used for designing and developing novel drugs directly aiming at the breast cancer tamoxifen resistance. The MiR-141 has the biological function and the action mechanism for promoting drug resistance of breast cancer cells and provides an effective way for effectively reversing the breast cancer tamoxifen resistance and improving the clinical chemotherapy effect on the breast cancer.

The invention provides a Fe (III) and Cu (II) doped polyaniline nano-compound and application thereof, belongs to the technical field of functional materials and particularly relates to a transition metal ion doped polyaniline nano-compound. The compound has good photo-thermal conversion, nuclear magnetic imaging and chemotherapy properties, can serve as a non-destructive tumor diagnosis and treatment reagent for nuclear magnetic imaging detection and thermo-chemotherapy on tumors. Copper (II) and iron (III) doped polyaniline nanoparticles are prepared through simple one-step reaction, the energy level of the conjugate structure of the polyaniline is changed after we support functional copper and iron metal ions in polyaniline having good biological compatibility, so that the extinction capability of the polyaniline in a near-infrared light area is remarkably improved, and the photo-thermal conversion performance is remarkably strengthened. In addition, the metal ion supported polyaniline nanoparticles have a good nuclear magnetic imaging function. The metal doped structure based on the coordination effect can also release the metal ions in a stimulated response environment, and the chemotherapy effect is produced by utilizing the toxicity of the metal ions.

The invention discloses application of a nilestriol compound in preparing an information treatment drug, a preparation method of the nilestriol compound and a novel drug prepared by the method. During the treatment, the information treatment drug does not directly touch a human body, drug substance components are not consumed, chemotherapy effects can be achieved only by drug information physiotherapy, and the therapy window is enlarged more than one thousand times, and side effects of the chemotherapy are avoided. After nilestriole is used as the information treatment drug, the effective component content is not changed, and nilestriole can be used secondarily and effectively as a chemotherapy normal preparation.

The invention discloses a functional liposome for treating lung cancer as well as a preparation method and an application of the functional liposome. The targeting liposome is prepared from lecithin, cholesterol, distearoyl phosphatidylethanolamine-polyethylene glycol and distearoyl phosphatidylethanolamine-polyethylene glycol-folic acid. According to the functional liposome provided by the invention, by modifying the DSPE-PEG2000-FA on the surface of liposome, an effect of targeting cancer cells is achieved; in the multifunctional lung cancer stem cell targeting compound liposome that an anti-tumor drug, namely hispidulin, and a tumor cell apoptosis inducer, namely EGCG, are entrapped in the liposome, the medicines (the hispidulin and the EGCG) can reach a focus part, and the two medicines, which are combined, can kill cancer cells and induce cancer stem cell apoptosis, so that a chemotherapy effect is greatly enhanced, and it is expected that the recurrence of the cancer can be effectively prevented. With the application of the functional liposome, it brings hope to the radical treatment of the lung cancer; therefore, the liposome has important theoretical significance and clinical significance.